系统综述:钆塞酸增强MRI对肝纤维化分期的诊断效能
该系统综述纳入20篇原始文献共1936例患者,采用双变量随机效应模型汇总分析,评估钆塞酸增强MRI对肝纤维化分期的诊断效能。汇总AUROC在≥F1、≥F2、≥F3和F4分别为0.92、0.87、0.89和0.91。样本量≥100例的研究敏感度84%、特异度91%,均显著高于样本量<100例研究的70%和77%;前瞻性设计研究敏感度94%、特异度94%,均显著高于回顾性设计的75%和84%。
要点
- 钆塞酸增强MRI对肝纤维化各期(≥F1至F4)汇总AUROC为0.87~0.92,诊断效能高。
- 样本量≥100例的研究敏感度84%、特异度91%,显著高于样本量<100例的70%和77%。
- 前瞻性设计研究敏感度94%、特异度94%,显著高于回顾性设计的75%和84%。
诊断标准与关键数值
- 钆塞酸增强MRI分期肝纤维化≥F1的汇总AUROC为0.92。
- 钆塞酸增强MRI分期肝纤维化≥F2的汇总AUROC为0.87。
- 钆塞酸增强MRI分期肝纤维化≥F3的汇总AUROC为0.89。
- 钆塞酸增强MRI分期肝纤维化F4的汇总AUROC为0.91。
- 样本量≥100例研究敏感度84%、特异度91%,样本量<100例研究敏感度70%、特异度77%(P<0.01);前瞻性研究敏感度94%、特异度94%,回顾性研究敏感度75%、特异度84%(P<0.01)。
临床应用与阅片要点
- 钆塞酸增强MRI可用于肝纤维化分期评估,阅片时需结合分期阈值(≥F1至F4)判读。
- 研究设计类型和样本量可能影响诊断效能估计,解读文献时需注意前瞻性大样本研究结果更优。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the diagnostic efficacy of gadoxetic acid-enhanced MRI for the staging of liver fibrosis by meta-analysis.
METHODS: PubMed/Medline, EMBASE, the Web of Science, and the Cochrane Library were searched. Studies were included according to their eligibility and the exclusion criteria. The Quality Assessment of Diagnostic Accuracy Studies 2 tool was used to assess the methodologic quality. The bivariate random-effects model was used to obtain the pooled summary estimates, heterogeneity, and the area under summary receiver operating characteristic curves (AUROC). Meta-regression was performed to discover the source of heterogeneity and compare certain some subsets for their capacity to stage hepatic fibrosis by AUROC comparison.
RESULTS: A total of 20 original articles (1936 patients) were included. Most studies had a low risk of bias and minimal concerns regarding applicability. The summary AUROC values of gadoxetic acid-enhanced MRI in staging the liver fibrosis ≥ F1, ≥ F2, ≥ F3, and F4 subsets were 0.92, 0.87, 0.89, and 0.91, respectively. Studies with populations equal to or more than 100 had a significantly higher sensitivity (84 %) and specificity (91 %) than those with populations less than 100 (70 % and 77 %, respectively, P < 0.01). Studies of a prospective design exhibited a significantly higher sensitivity (94 %) and specificity (94 %) than those of a retrospective design (75 % and 84 %, respectively, P < 0.01).
CONCLUSIONS: Our meta-analysis shows the high diagnostic efficacy of gadoxetic acid-enhanced MRI in the staging of liver fibrosis. A prospective study with more than one hundred patients showed higher diagnostic efficacy.
引用
- Yang D, Li D, Li J, et al. Systematic review: The diagnostic efficacy of gadoxetic acid-enhanced MRI for liver fibrosis staging. Eur J Radiol. 2020. PMID: 32113153. doi:10.1016/j.ejrad.2020.108857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。